Jazz Pharmaceuticals PLC (JAZZ)

132.00 -2.82  -2.09% NASDAQ Feb 24, 16:59 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
05/07/2020 16:30 EDT Misc Jazz Pharmaceuticals PLC First Quarter Earnings Conference Call in 2020
05/07/2020 Earnings Jazz Pharmaceuticals PLC First Quarter Earnings in 2020 Release
02/25/2020 16:30 EST Misc Jazz Pharmaceuticals PLC Fourth Quarter Earnings Conference Call for 2019
02/25/2020 Earnings Jazz Pharmaceuticals PLC Fourth Quarter Earnings in 2019 Release
11/05/2019 16:30 EST Misc Jazz Pharmaceuticals PLC Third Quarter Earnings Conference Call for 2019
11/05/2019 Earnings Jazz Pharmaceuticals PLC Third Quarter Earnings in 2019 Release
08/06/2019 16:30 EDT Misc Jazz Pharmaceuticals PLC Second Quarter Earnings Conference Call for 2019
08/06/2019 Earnings Jazz Pharmaceuticals PLC Second Quarter Earnings Results for 2019
08/01/2019 Misc Jazz Pharmaceuticals PLC Annual General Meeting in 2018
05/07/2019 16:30 EDT Misc Jazz Pharmaceuticals PLC First Quarter Earnings Conference Call in 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.jazzpharmaceuticals.com
  • Investor Relations URL: http://investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-irhome
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Blend
  • Next Earnings Release: Feb. 25, 2020
  • Last Earnings Release: Nov. 05, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, as well as Erwinaze for acute lymphoblastic leukemia, Defitelio for severe veno-occlusive disease after stem cell transplant, and Vyxeos for acute myeloid leukemia.

Top Fund Holders

Symbol Name Weighting
PVSRX Putnam Capital Spectrum R 9.76%
PYSRX Putnam Equity Spectrum R 9.62%
XPH SPDR® S&P Pharmaceuticals ETF 3.78%
IHE iShares US Pharmaceuticals ETF 3.01%
PPH VanEck Vectors Pharmaceutical ETF 2.83%
RBF1092 RBC U.S. Mid-Cap Value Equity Fund D 2.34%
FXH First Trust Health Care AlphaDEX® ETF 1.92%
FZAKX Fidelity Advisor® Leveraged Co Stk Z 1.92%
HNTVX Heartland Value Institutional 1.83%
JSMD Janus Henderson Small/Md Cp Gr Alpha ETF 1.78%
FIDFX Fidelity Advisor® Mid Cap Value Z 1.41%
IBB iShares Nasdaq Biotechnology ETF 0.91%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.